Cleo Diagnostics has partnered with a US healthcare consultancy to promote its ovarian cancer blood test in the United States.
In this interview, Cleo Diagnostics CEO Dr Richard Allman explains how recently released clinical data shows its test kits are better at identifying cancers overall, including early stage cancers; and can provide far greater confidence in elimination of “false positive” findings, where patients have benign growths.
Cleo Diagnostics has recently partnered with HCFocus, a New York-based strategic healthcare consultancy, to help develop Cleo’s US market access program whilst test kit manufacturing commences.
